Business Wire05.26.17
Lombard Medical Inc., a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, has enrolled and treated the first patient in its global registry to evaluate its Altura Endograft System.
The ALTITUDE registry (ALTura Impact on the Treatment of Abdominal Aortic Aneurysms Using a Novel D-stent EVAR Design) is being conducted across a range of United Kingdom and international clinical centers to evaluate the use of the Altura Endograft System in 1,000 patients in typical clinical-use conditions.
ALTITUDE’s chief investigator, Paul Hayes, M.D., F.R.C.S., Department of Surgery, University of Cambridge and Addenbrooke’s Hospital, Cambridge, United Kingdom, commented, “This registry will allow the clinical community of AAA implanters to gain necessary experience with Altura. Given the system’s ultra-low profile, its repositionability, the elimination of the contralateral cannulation step and retrograde delivery of the limb sections, this design promises to facilitate a much simpler, faster, more predictable and consistent deployment of the endograft. The launch of this registry confirms Lombard’s confidence in the product and will allow us to develop a robust dataset about long-term outcomes.”
“I am encouraged by our positive early clinical experience with Altura. The simplicity of planning, accuracy of deployment and repositionability could lead to it becoming a workhorse device in the future. The ALTITUDE registry will provide a real world evaluation of the longer term outcomes,” said Simon Kreckler, M.D., F.R.C.S., vascular and endovascular surgeon at Addenbrooke’s Hospital, Cambridge, United Kingdom.
Lombard Medical Inc., based in Oxfordshire, United Kingdom, develops, manufactures and markets a range of minimally invasive abdominal aortic aneurysm endovascular repair products.
The ALTITUDE registry (ALTura Impact on the Treatment of Abdominal Aortic Aneurysms Using a Novel D-stent EVAR Design) is being conducted across a range of United Kingdom and international clinical centers to evaluate the use of the Altura Endograft System in 1,000 patients in typical clinical-use conditions.
ALTITUDE’s chief investigator, Paul Hayes, M.D., F.R.C.S., Department of Surgery, University of Cambridge and Addenbrooke’s Hospital, Cambridge, United Kingdom, commented, “This registry will allow the clinical community of AAA implanters to gain necessary experience with Altura. Given the system’s ultra-low profile, its repositionability, the elimination of the contralateral cannulation step and retrograde delivery of the limb sections, this design promises to facilitate a much simpler, faster, more predictable and consistent deployment of the endograft. The launch of this registry confirms Lombard’s confidence in the product and will allow us to develop a robust dataset about long-term outcomes.”
“I am encouraged by our positive early clinical experience with Altura. The simplicity of planning, accuracy of deployment and repositionability could lead to it becoming a workhorse device in the future. The ALTITUDE registry will provide a real world evaluation of the longer term outcomes,” said Simon Kreckler, M.D., F.R.C.S., vascular and endovascular surgeon at Addenbrooke’s Hospital, Cambridge, United Kingdom.
Lombard Medical Inc., based in Oxfordshire, United Kingdom, develops, manufactures and markets a range of minimally invasive abdominal aortic aneurysm endovascular repair products.
